Michael E. Shy

17.7k total citations
246 papers, 11.0k citations indexed

About

Michael E. Shy is a scholar working on Cellular and Molecular Neuroscience, Neurology and Molecular Biology. According to data from OpenAlex, Michael E. Shy has authored 246 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 200 papers in Cellular and Molecular Neuroscience, 94 papers in Neurology and 67 papers in Molecular Biology. Recurrent topics in Michael E. Shy's work include Hereditary Neurological Disorders (192 papers), Genetic Neurodegenerative Diseases (83 papers) and Botulinum Toxin and Related Neurological Disorders (55 papers). Michael E. Shy is often cited by papers focused on Hereditary Neurological Disorders (192 papers), Genetic Neurodegenerative Diseases (83 papers) and Botulinum Toxin and Related Neurological Disorders (55 papers). Michael E. Shy collaborates with scholars based in United States, Italy and United Kingdom. Michael E. Shy's co-authors include Mary M. Reilly, John Kamholz, Richard A. Lewis, Carly E. Siskind, Karen Krajewski, Steven S. Scherer, Shawna Feely, James Garbern, Jun Li and Ágnes Patzkó and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Neuron.

In The Last Decade

Michael E. Shy

240 papers receiving 10.7k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Michael E. Shy 7.1k 4.0k 3.4k 2.1k 1.6k 246 11.0k
Angelo Quattrini 3.6k 0.5× 2.1k 0.5× 3.8k 1.1× 1.3k 0.6× 1.4k 0.9× 228 9.7k
Davide Pareyson 4.5k 0.6× 3.6k 0.9× 2.4k 0.7× 1.3k 0.6× 723 0.4× 252 7.9k
Rudolf Martini 6.3k 0.9× 2.0k 0.5× 3.2k 0.9× 1.7k 0.8× 1.4k 0.8× 159 9.5k
Kristján R. Jessen 9.9k 1.4× 1.9k 0.5× 5.0k 1.4× 869 0.4× 1.1k 0.7× 139 14.4k
Wolfram Tetzlaff 7.9k 1.1× 1.3k 0.3× 4.1k 1.2× 2.8k 1.3× 871 0.5× 201 15.9k
Peter De Jonghe 6.6k 0.9× 2.5k 0.6× 5.4k 1.6× 2.2k 1.0× 1.9k 1.2× 235 13.0k
Alan Pestronk 4.4k 0.6× 7.4k 1.9× 5.4k 1.6× 1.3k 0.6× 1.4k 0.8× 242 15.3k
Mark Armanini 5.9k 0.8× 2.0k 0.5× 7.3k 2.1× 688 0.3× 777 0.5× 52 14.4k
Marc Peschanski 5.5k 0.8× 2.1k 0.5× 5.3k 1.6× 859 0.4× 473 0.3× 224 10.8k
Wilfred F.A. den Dunnen 2.9k 0.4× 1.5k 0.4× 2.9k 0.8× 1.2k 0.6× 447 0.3× 177 7.6k

Countries citing papers authored by Michael E. Shy

Since Specialization
Citations

This map shows the geographic impact of Michael E. Shy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Shy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Shy more than expected).

Fields of papers citing papers by Michael E. Shy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael E. Shy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Shy. The network helps show where Michael E. Shy may publish in the future.

Co-authorship network of co-authors of Michael E. Shy

This figure shows the co-authorship network connecting the top 25 collaborators of Michael E. Shy. A scholar is included among the top collaborators of Michael E. Shy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael E. Shy. Michael E. Shy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
White, Amy, Tiffany Grider, Josef Alawneh, et al.. (2024). P004: Urine polyols for diagnosis of sorbitol dehydrogenase (SORD) deficiency-related peripheral neuropathy*. SHILAP Revista de lepidopterología. 2. 100881–100881.
3.
Dilek, Nuran, Janet E. Sowden, Katy Eichinger, et al.. (2024). Patient‐reported disease burden in the Accelerate Clinical Trials in Charcot–Marie–Tooth Disease Study. Journal of the Peripheral Nervous System. 29(4). 487–493. 1 indexed citations
4.
Sadjadi, Reza, Vincent Picher‐Martel, Jasper M. Morrow, et al.. (2024). Clinical Characteristics of Charcot-Marie-Tooth Disease Type 4J. Neurology. 103(5). e209763–e209763. 2 indexed citations
5.
Mandarakas, Melissa R., Katy Eichinger, Paula Bray, et al.. (2024). Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure. Neurology. 102(3). e207963–e207963. 4 indexed citations
6.
Sondheimer, Neal, Jessie M. Cameron, Hernán Gonorazky, et al.. (2023). Biallelic pathogenic variants in the mitochondrial form of phosphoenolpyruvate carboxykinase cause peripheral neuropathy. Human Genetics and Genomics Advances. 4(2). 100182–100182. 1 indexed citations
7.
Wu, Tong, Richard S. Finkel, Carly E. Siskind, et al.. (2023). Validation of the parent‐proxy version of the pediatric Charcot‐Marie‐Tooth disease quality of life instrument for children aged 0–7 years. Journal of the Peripheral Nervous System. 28(3). 382–389. 4 indexed citations
8.
Cornett, Kayla, Sarah P. Garnett, Rosemary Shy, et al.. (2023). Association of Body Mass Index With Disease Progression in Children With Charcot-Marie-Tooth Disease. Neurology. 101(7). e717–e727. 3 indexed citations
9.
Wu, Tong, Davide Pareyson, Richard A. Lewis, et al.. (2023). Neuropathy due to bi-allelic SH3TC2 variants: genotype-phenotype correlation and natural history. Brain. 146(9). 3826–3835. 10 indexed citations
10.
Silsby, Matthew, Eva L. Feldman, Richard Dortch, et al.. (2023). Advances in diagnosis and management of distal sensory polyneuropathies. Journal of Neurology Neurosurgery & Psychiatry. 94(12). 1025–1039. 6 indexed citations
11.
Reilly, Mary M., David N. Herrmann, Davide Pareyson, et al.. (2023). Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints. Annals of Neurology. 93(5). 906–910. 12 indexed citations
12.
Moroni, Isabella, Federica Rachele Danti, Davide Pareyson, et al.. (2022). Validation of the Italian version of the pediatric CMT quality of life outcome measure. Journal of the Peripheral Nervous System. 27(2). 127–130. 4 indexed citations
13.
Wang, Hongge, Matt Davison, Katherine M. Call, et al.. (2021). MicroRNAs as Biomarkers of Charcot-Marie-Tooth Disease Type 1A. Neurology. 97(5). e489–e500. 18 indexed citations
14.
Bray, Paula, Kayla Cornett, Davide Pareyson, et al.. (2020). Reliability of the Charcot‐Marie‐Tooth functional outcome measure. Journal of the Peripheral Nervous System. 25(3). 288–291. 9 indexed citations
15.
Cornett, Kayla, Manoj P. Menezes, Paula Bray, et al.. (2020). Refining clinical trial inclusion criteria to optimize the standardized response mean of the CMTPedS. Annals of Clinical and Translational Neurology. 7(9). 1713–1715. 15 indexed citations
16.
Franco, Antonietta, Barbara Zabłocka, Cindy V. Ly, et al.. (2020). Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A. eLife. 9. 42 indexed citations
17.
Fratta, Pietro, Francesca Ornaghi, Gabriele Dati, et al.. (2018). A nonsense mutation in myelin protein zero causes congenital hypomyelination neuropathy through altered P0 membrane targeting and gain of abnormal function. Human Molecular Genetics. 28(1). 124–132. 18 indexed citations
18.
Jerath, Nivedita U., Steven A. Moore, Michael E. Shy, et al.. (2015). Rare Manifestation of a c.290 C>T, p.Gly97GluVCPMutation. SHILAP Revista de lepidopterología. 2015. 1–5. 16 indexed citations
19.
Feely, Shawna, Matilde Laurá, Carly E. Siskind, et al.. (2011). MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology. 76(20). 1690–1696. 154 indexed citations
20.
Li, J., et al.. (2007). Stoichiometric alteration of PMP22 protein determines the phenotype of HNPP. Journal of the Peripheral Nervous System. 12. 52–52. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angelo Quattrini Breakdown of academic impact, for papers by Davide Pareyson Breakdown of academic impact, for papers by Rudolf Martini Breakdown of academic impact, for papers by Kristján R. Jessen Breakdown of academic impact, for papers by Wolfram Tetzlaff Breakdown of academic impact, for papers by Peter De Jonghe Breakdown of academic impact, for papers by Alan Pestronk Breakdown of academic impact, for papers by Mark Armanini Breakdown of academic impact, for papers by Marc Peschanski Breakdown of academic impact, for papers by Wilfred F.A. den Dunnen
Rankless by CCL
2026